Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.
Broad-market heuristics · Not a buy/sell signal
Valuation and growth
Valuation
Growth
Negative earnings, no valuation support
25–30x, paying up for cash generation
Below 2%, essentially flat
Below 2%, essentially flat
Business Quality & Capital Allocation
Mild dilution under 2%
Modest contraction, within normal range
Net debt/FCF of 1.5x, somewhat elevated
Below 8%, may not cover cost of capital
Vitrolife AB (VITR.XSTO) quality: score, margins and returns
Vitrolife AB (VITR.XSTO) scores 22/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 7 metrics each scored 0 to 100, on 18.7% operating margins and 3.6% ROIC. Every metric is computed from company filings; this is analysis, not investment advice.
Frequently asked
Is Vitrolife AB (VITR.XSTO) a high-quality business?+
Vitrolife AB scores 22 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Recent figures include a 18.7% operating margin and a 3.6% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.
What does Vitrolife AB's quality score measure?+
Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from VITR.XSTO's company filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Vitrolife AB scores well and where it falls behind.
What is Vitrolife AB's return on invested capital (ROIC)?+
Vitrolife AB earns about 3.6% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to VITR.XSTO's margins and growth on this scorecard to judge durability.
How profitable is Vitrolife AB?+
Vitrolife AB runs an operating margin of about 18.7% and a net margin of about -146.9%. Revenue has grown at roughly 19.6% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from company filings, not investment advice.
Peers
Medical Devices · Pick stocks to compare with VITR.XSTO
Held by ETFs
VITR.XSTO is in 4 US ETFs. The largest of them, with VITR.XSTO's weight in each:
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing VITR.XSTO
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.